DanCann Pharma in Multi-Level Expansion of Precision Aeroponic Systems to Fulfill Export Contracts

The Danish Medicinal Cannabis Producer is Scaling AEssenseGrows Systems in Their EU-GMP Certified Facility to Full Production Capacity

DanCann Pharma (SS:DANCAN)

SANTA CLARA, CA, UNITED STATES, May 17, 2023/EINPresswire.com/ — AEssenseGrows, an AgTech company specializing in precision automated aeroponic platforms for software controlled high-yield plant production announced today, that DanCann Pharma, a medicinal cannabis company based in Denmark, is building out their entire capacity with 1, 2, and 4-Layer AEtrium Systems. With no deviations in their final Developmental inspection by the Danish Medicines Agency, DanCann plans for 80M DKK (~$11M USD) shipments to Germany and Poland from the immediate production ramp from 2023 to 2025.

“After finishing 3 grow cycles in our facility for validation, we will have qualified for commercial production with zero irradiation. This is pure and perfectly sterile aeroponic cannabis flower.”, said Morten Martinsen, Co-Founder and Head of Business Development, DanCann Pharma. “Everything we do, we do for the patient and aeroponics enables us to deliver unspoiled products without any contamination or degradation from the irradiation process.” Morten continued.

“The team at DanCann has crafted a completely unique grow recipe that we have not seen perfected by previous customers. Their method uses less than half the typical fertilizer content with amazing results.”, stated Michael Jorgensen, Managing Director, AEssenseGrows. “Their minimal salts aeroponic approach provides a very clean grow process with no biofilm build-up”, said Jorgensen.

DanCann has been testing many new strains over the last year with their favorites being Kush variants and several high THC hybrids and phenotypes. With standard operating procedures and workflows captured in the revolutionary Guardian Grow Manager software, DanCann has fingertip control over their entire scaled facility from one dashboard. The team expects to ramp output 20X over the next year. Already at full employment, full automation will allow the complete production ramp with minimal additional labor.

DanCann is producing pharma-grade premium cannabis for existing contracts. Current capacity, including the latest Double Deck AEtrium deliveries, is sold out through the end of 2024.

About AEssenseGrows
AEssenseGrows (pronounced “essence grows”), founded in 2014, is a precision AgTech company based in Santa Clara, CA. AEssenseGrows provides accelerated plant growth SmartFarm platforms and software automation delivering pure, zero pesticide, year-round, enriched growth to fresh produce and medicinal plant producers globally. With AEssenseGrows, you can precisely control your production operations at your fingertips from anywhere in the world. For more information, visit: https://www.AEssenseGrows.com

About DanCann Pharma
DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution company based in Denmark. The company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

DanCann Pharma A/S (SS:DANCAN) is listed on the Spotlight Stock Market in Stockholm/Copenhagen and on OTC Venture Market in the US (DCPXF). The corporate introduction video can be seen at: https://www.aessensegrows.com/aeroponic-medicinal-manufacturing-beyond-gmp-gacp-standards-dancann-pharma
For more information, visit: https://www.dancann.com

Disclaimer
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Phil Gibson
AEssenseGrows
+ +1 669-261-3086
[email protected]
Visit us on social media:
Facebook
Twitter
LinkedIn
Instagram
YouTube
TikTok

DanCann Pharma: For those left behind